Cover Image
市場調查報告書

全球RNA治療市場(各技術、引進疾病區分、終端用戶、地區):市場規模與預測、全球的趨勢、需求及市場機會分析、市場佔有率、企業簡介等

Global RNA Based Therapeutics Market (Technology, Application, End Users and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020

出版商 Allied Market Research 商品編碼 316199
出版日期 內容資訊 英文 140 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球RNA治療市場(各技術、引進疾病區分、終端用戶、地區):市場規模與預測、全球的趨勢、需求及市場機會分析、市場佔有率、企業簡介等 Global RNA Based Therapeutics Market (Technology, Application, End Users and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020
出版日期: 2014年09月14日 內容資訊: 英文 140 Pages
簡介

RNA為基礎治療方法,據信具有治療包含癌症和糖尿病、愛滋病、結核、部分心臟疾病症狀等各種慢性疾病的高潛力,近幾年大受注目。這個治療方法,雖然尚處於臨床試驗階段,但研究為治癒困難疾病的有潛力治療選項。這個治療方法的開發,是基於RNA干擾技術(RNAi),反義核酸技術、 SMaRT技術等有希望的技術。

本報告提供RNA為基礎治療方法的市場相關的詳細調查、利用RNA的技術類型和概要、可應用的疾病領域、各技術區分、引進目標的疾病領域、終端用戶、地區的市場規模的變化與預測、市場的各種影響因素分析、開發平台趨勢、主要經營者的配合措施、簡介等彙整資料。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義、範圍
  • 到現在為止的過程、目前市場趨勢
  • SMART RNA技術:為了確認引起疾病的RNA的確實工具
  • 傳統 vs RNA為基礎的治療
  • 可尋址市場分析
    • DNA的治療
    • RNA的治療
  • 主要調查結果
    • RNA治療市場的主要影響因素
    • RNA治療市場主要投資口袋
    • RNA治療市場主要成功策略
  • 相關法律
    • USFDA
    • EU
  • 波特的五力分析
  • 價值鏈分析
  • 開發平台分析
  • 專利分析
  • RNA為基礎的治療的臨床試驗
  • 市場動態
    • 成長推進因素
    • 阻礙成長要素
    • 市場機會

第4章 章 全球RNA治療市場預測:各技術

  • 實行技術
    • 微陣列
    • 標籤
    • 純化
    • 線性擴增
    • qRT-PCR
    • 抑制
  • 實現的技術
    • RNA干擾(RNAi)技術
      • 市場動態
      • 競爭模式
      • siRNA
      • MicroRNA(miRNA)
      • 市場規模與預測
    • RNA反義技術
      • 市場動態
      • 競爭模式
      • 市場規模與預測

第5章 全球RNA治療市場預測:各疾病種類

  • 心臟疾病
    • 全球發病率
    • 引進推進因素
    • 市場規模與預測
  • 腎臟疾病
    • 全球發病率
    • 引進推進因素
    • 市場規模與預測
  • 癌症
    • 全球發病率
    • 引進推進因素
    • 市場規模與預測
  • 感染疾病
    • 全球發病率
      • 結核
      • HIV、AIDS
    • 引進推進因素
    • 市場規模與預測
  • 代謝異常
    • 全球發病率
      • 肥胖
      • 糖尿病
    • 引進推進因素
    • 市場規模與預測
  • 其他

第6章 全球RNA治療市場預測:各終端用戶

  • 研究
  • 治療
  • 診斷

第7章 全球RNA治療市場預測:各地區

  • 北美
    • 美國
      • 開發平台的檢討
      • 主要的市場趨勢
      • 競爭模式
      • 主要的成長推進因素、市場機會
    • 加拿大
      • 開發平台的檢討
      • 主要的市場趨勢
      • 競爭模式
      • 主要的成長推進因素、市場機會
  • 歐洲
    • 德國
      • 開發平台的檢討
      • 主要的市場趨勢
      • 競爭模式
      • 主要的成長推進因素、市場機會
    • 英國
      • 開發平台的檢討
      • 主要的市場趨勢
      • 競爭模式
      • 主要的成長推進因素、市場機會
    • 法國
    • 其他
  • 亞太地區
    • 開發平台的檢討
    • 主要的市場趨勢
    • 競爭模式
    • 主要的成長推進因素、市場機會
    • 市場規模與預測
  • 中南美
    • 開發平台的檢討
    • 主要的市場趨勢
    • 競爭模式
    • 主要的成長推進因素、市場機會
    • 市場規模與預測

第8章 企業簡介

  • Quark Pharmaceuticals, Inc.(美國)
  • Alnylam Pharmaceuticals, Inc.(美國)
  • Dicerna Pharmaceuticals, Inc.(美國)
  • Tekmira Pharmaceuticals Corp.(加拿大)
  • Benitec Biopharma Limited (澳洲)
  • Cenix BioScience GmbH (德國)
  • Genzyme Corporation(美國)(Sanofi系列)
  • Silence Therapeutics PLC(英國)
  • Sirnaomics, Inc.(美國)
    • 企業概要
    • 策略性配合措施
    • SWOT分析等

圖表

目錄
Product Code: PH 14546

RNA based therapeutics has garnered significant attention in the recent years due to its potential to treat variety of chronic diseases such as cancer, diabetes, AIDS, Tuberculosis and certain cardiovascular conditions. Despite being in the clinical research phase, the RNA based therapeutics is been explored as a promising treatment option for the diseases which are difficult to treat. Development of this therapeutics is based on promising technologies such as RNA interference technology (RNAi), antisense technology and SMaRT technology. RNAi technology and antisense technology together are gaining prominence in the research industry, as these technologies provide base sequence to develop RNA drugs. RNAi technology works by causing destruction of specific mRNA molecules; whereas, antisense technology works by synthesizing strand of RNA from known gene sequence. These newly synthesized RNA strands then itself binds to mRNA and make mRNA inactive. Gene silencing potential of RNA based therapeutics is the primary driver for the growth of this market. The other drivers include target specificity and selectivity of RNAi therapeutics, more intense product focus versus platform technologies and virtual drug development models that enable companies to reduce the research cost. However, critical issues in drug delivery, high cost of research, and high failure rates are some of the major hurdles for the companies working in this field. Despite the restraints, RNA based therapeutics has the potential to grow due to increasing interest exhibited by the pharmaceutical industries for the commercialization of these therapies. Quark Pharmaceuticals, Inc. (USA), Alnylam Pharmaceuticals, Inc. (USA), Dicerna Pharmaceuticals, Inc. (USA), Tekmira Pharmaceuticals Corp. (Canada), Benitec Biopharma Limited (Australia), Genzyme Corporation (USA), ISIS pharmaceuticals Inc (USA), Silence Therapeutics PLC (UK) and Cenix BioScience GmbH (Germany) are some of the key players in this market. ISIS pharmaceuticals, Inc. (USA) has focused its research activities on antisense technology and developed antisense therapeutics, namely Mipomersen and Fomivirsen. This therapeutics is commercially available in the market and marketed as Kynamro and Vitravene respectively. Quark, Alnylam and silence therapeutics are other major players of this market with strong research pipeline in RNA based therapeutics.

RNA based therapeutics market is segmented into technology, application, end-users and geography. Technology segment is further categorized as enabling technologies and enabled technologies. The segment of enabling technologies comprises of Microarrays, Labeling, Purification, Linear amplification, qRT-PCR and Inhibition; whereas, enabled technologies includes RNA interference technology (RNAi) and RNA antisense technology. Enabled technologies account for largest market share due to their potential use in therapeutics. The market for RNA based therapeutics is dominated by RNA interference technology as numerous companies have exhibited their interest to develop the RNA drugs using RNAi technology. RNA based therapeutics have wide applications covering variety of chronic conditions such as Cardiovascular, Kidney Diseases, Oncology, Infectious diseases, Metabolic disorders and Others. The pipeline research is concentrated towards oncology and infectious diseases due to their high prevalence and failure of existing treatment to effectively treat these conditions. The end user market is segmented into research, therapeutics and diagnostics. Currently, research and diagnostics segments are largely exploring the RNA technologies and therapies for the commercialization of RNA drugs.

Geographically, RNA based therapeutics market is segmented into North America, Europe, Asia-Pacific and LAMEA. Potential regions of the respective geographies are strategically analyzed to provide country wise focus on RNA research activities. North America dominates the RNA based therapeutics followed by Europe and Asia-Pacific. The key market players belong to North America and are conducting extensive research to commercialize the therapeutics. Moreover, the growth in North America and Europe is primarily driven by substantial investment on research, advancement in RNA platform technologies, government support and availability of suitable infrastructure to develop the novel RNA based therapies. However, business dynamics in Asia-pacific is anticipated to offer tremendous opportunities to major players of this market as cost of clinical research is less in this region as compared to North America and Europe.

KEY BENEFITS

  • An in-depth analysis of research and clinical developments within RNA based therapeutics market is provided and light is shed on market dynamics that would prove crucial in understanding the market
  • Quantitative analysis of the current market and estimations through 2013-2020 would assist strategists to design business strategies to capitalize on the prevailing opportunities in the market
  • Competitive structure of RNA based therapeutics market is analyzed through Porter's Five Forces model and provides in-depth understanding of the influencing factors for commercialization of RNA therapeutics
  • Detailed study of the strategies of key leaders, partnerships, acquisitions and clinical trials in the RNA based therapeutics market would be informative for professionals in the corporate sector
  • Pin-point analysis of geographic segments would assist in identification of most profitable segments to capitalize on

KEY MARKET SEGMENTS

RNA based therapeutics market is segmented into four major categories such as Technology, Application, End Users and Geography.

MARKET BY TECHNOLOGY

  • Enabling technologies
    • Microarrays
    • Labeling
    • Purification
    • Linear amplification
    • qRT-PCR
    • Inhibition
  • Enabled technologies
    • RNA Interference (RNAi) technologies
      • Small interfering RNA (siRNA)
      • MicroRNA (miRNA)
    • RNA antisense technologies

MARKET BY APPLICATION

  • Cardiovascular
  • Kidney Diseases
  • Oncology
  • Infectious diseases
  • Metabolic disorders
  • Others

MARKET BY END USERS

  • Research
  • Therapeutics
  • Diagnosis

MARKET BY GEOGRAPHY

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Others
  • Asia Pacific
  • LAMEA

Table of Contents

CHAPTER 1-INTRODUCTION

  • 1.1. Report Description
  • 1.2. Reason for doing the study
  • 1.3. Key Benefits
  • 1.4. Key Market Segments
  • 1.5. Key Audiences
  • 1.6. Research Methodology
    • 1.6.1. Secondary Research
    • 1.6.2. Primary Research
    • 1.6.3. Analyst tools and models

CHAPTER 2-EXECUTIVE SUMMARY

  • 2.1. CXO perspective
  • 2.2. Market beyond what to expect by 2025
    • 2.2.1. Moderate growth scenario
    • 2.2.2. Rapid growth scenario
    • 2.2.3. Diminishing growth scenario

CHAPTER 3-MARKET OVERVIEW

  • 3.1. Market Definition and Scope
  • 3.2. Historical perspective and current market trends
  • 3.3. SMaRT RNA Technology- A promising Tool To Target Disease Causing RNAs
  • 3.4. Conventional Vs RNA-based therapeutics
  • 3.5. Addressable Market Analysis
    • 3.5.1. DNA based therapeutics
    • 3.5.2. RNA based thearpeutics
  • 3.6. Key Findings
    • 3.6.1. Top Factors Impacting on RNA based therapeutics market
    • 3.6.2. Top Investment Pockets of RNA based therapeutics market
    • 3.6.3. Top winning strategies of RNA based therapeutics market
  • 3.7. Government Regulations
    • 3.7.1. USFDA Perspective
    • 3.7.2. European Union Perspective
  • 3.8. Porter five force model
    • 3.8.1. Bargaining power of buyers (Low)
    • 3.8.2. Bargaining power of suppliers(High)
    • 3.8.3. Threat of new entrants (High)
    • 3.8.4. Threat of substitute products (Moderate)
    • 3.8.5. Intensity of competitive rivalry (Strong)
  • 3.9. Value chain analysis
    • 3.9.1. Primary activities
    • 3.9.2. Support Activities
  • 3.10. Pipeline Review
  • 3.11. Patent Analysis
    • 3.11.1. Patent analysis by geographies(2010-2014)
  • 3.12. Clinical Trials For RNA Based Therapeutics
  • 3.13. Market Dynamics
    • 3.13.1. Drivers
      • 3.13.1.1. Target specificty and selectivity of treatment
      • 3.13.1.2. Strategic Alliances and Funding
      • 3.13.1.3. More intense product focus against platform technology
      • 3.13.1.4. Promising technologies driving the RNA based therapeutics
      • 3.13.1.5. Adoption of virtual drug development models
    • 3.13.2. Restraints
      • 3.13.2.1. Hurdles in drug delivery
      • 3.13.2.2. High cost of research and threat of failure
    • 3.13.3. Opportunities
      • 3.13.3.1. Early commercialization of pipeline therapeutics assists to gain competitive advantage
      • 3.13.3.2. Multifactorial disease targeting

CHAPTER 4-GLOBAL RNA BASED THERAPEUTICS MARKET BY TECHNOLOGIES, 2013-2020, $MILLION

  • 4.1. Enabling technologies
    • 4.1.1. Microarrays
    • 4.1.2. Labelling
    • 4.1.3. Purification
    • 4.1.4. Linear amplification
    • 4.1.5. qRT-PCR
    • 4.1.6. Inhibition
  • 4.2. Enabled technologies
    • 4.2.1. RNA Interference (RNAi) technologies
      • 4.2.1.1. Market Dynamics
        • 4.2.1.1.1. DRIVERS
        • 4.2.1.1.2. RESTRAINTS
        • 4.2.1.1.3. OPPORTUNITIES
      • 4.2.1.2. Competitive scenario
      • 4.2.1.3. Small interfering RNA (siRNA)
      • 4.2.1.4. MicroRNA (miRNA)
      • 4.2.1.5. Market size & forecast
    • 4.2.2. RNA antisense technologies
      • 4.2.2.1. Market Dynamics
        • 4.2.2.1.1. DRIVERS
        • 4.2.2.1.2. RESTRAINTS
        • 4.2.2.1.3. OPPORTUNITIES
      • 4.2.2.2. Competitive scenario
      • 4.2.2.3. Market size & forecast

CHAPTER 5-GLOBAL RNA BASED THERAPEUTICS MARKET BY APPLICATIONS, 2013-2020, $MILLION

  • 5.1. Cardiovascular
    • 5.1.1. Global Cardiac Disease Incidences
      • 5.1.1.1. Facts for cardiac diseases
    • 5.1.2. Adoption Drivers
    • 5.1.3. Market Size and Forecast
  • 5.2. Kidney Diseases
    • 5.2.1. Global Renal Disease Incidences
    • 5.2.2. Adoption Drivers
    • 5.2.3. Market Size and Forecast
  • 5.3. Oncology
    • 5.3.1. Global Cancer Incidences
    • 5.3.2. Adoption Drivers
    • 5.3.3. Market Size and Forecast
  • 5.4. Infectious diseases
    • 5.4.1. Global Infectious Disease Incidences
      • 5.4.1.1. Tuberculosis
      • 5.4.1.2. HIV and AIDS
    • 5.4.2. Adoption Drivers
    • 5.4.3. Market Size and Forecast
  • 5.5. Metabolic disorders
    • 5.5.1. Global Metabolic Disorders by Type
      • 5.5.1.1. Obesity
      • 5.5.1.2. Diabetes
    • 5.5.2. Adoption Drivers
    • 5.5.3. Market Size and Forecast
  • 5.6. Others

CHAPTER 6-GLOBAL RNA BASED THERAPEUTICS MARKET BY END USERS, 2013-2020, $MILLION

  • 6.1. Research
  • 6.2. Therapeutics
  • 6.3. Diagnosis

CHAPTER 7-GLOBAL RNA BASED THERAPEUTICS MARKET BY GEOGRAPHY, 2013-2020, $MILLION

  • 7.1. North America
    • 7.1.1. United States
      • 7.1.1.1. Pipeline Review
      • 7.1.1.2. Market Trends
      • 7.1.1.3. Competitive scenario
      • 7.1.1.4. Key growth factors and opportunities
    • 7.1.2. Canada
      • 7.1.2.1. Pipeline Review
      • 7.1.2.2. Key market trends
      • 7.1.2.3. Competitive scenario
      • 7.1.2.4. Key growth factors and opportunities
  • 7.2. Europe
    • 7.2.1. Germany
      • 7.2.1.1. Pipeline Review
      • 7.2.1.2. Key market trends
      • 7.2.1.3. Competitive scenario
      • 7.2.1.4. Key growth factors and opportunities
    • 7.2.2. United Kingdom
      • 7.2.2.1. Pipeline Review
      • 7.2.2.2. Key market trends
      • 7.2.2.3. Competitive scenario
      • 7.2.2.4. Key growth factors and opportunities
    • 7.2.3. France
    • 7.2.4. Others
  • 7.3. Asia-Pacific
    • 7.3.1. Pipeline Review
    • 7.3.2. Key market trends
    • 7.3.3. Competitive scenario
    • 7.3.4. Key growth factors and opportunities
    • 7.3.5. Market size and forecast
  • 7.4. LAMEA
    • 7.4.1. Pipeline Review
    • 7.4.2. Key market trends
    • 7.4.3. Competitive scenario
    • 7.4.4. Key growth factors and opportunities
    • 7.4.5. Market size and forecast

CHAPTER 8-COMPANY PROFILES

  • 8.1. Quark Pharmaceuticals, Inc. (USA)
    • 8.1.1. Company overview
    • 8.1.2. Company snapshots
    • 8.1.3. Strategic moves and developments
      • 8.1.3.1. Principal Strategy
      • 8.1.3.2. Secondary Strategy
    • 8.1.4. SWOT Analysis
  • 8.2. Alnylam Pharmaceuticals, Inc. (USA)
    • 8.2.1. Company overview
    • 8.2.2. Company snapshots
    • 8.2.3. Business Performance
    • 8.2.4. Strategic moves and developments
      • 8.2.4.1. Principal Strategy
      • 8.2.4.2. Secondary Strategy
    • 8.2.5. SWOT Analysis
  • 8.3. Dicerna Pharmaceuticals, Inc. (USA)
    • 8.3.1. Company overview
    • 8.3.2. Company snapshots
    • 8.3.3. Business Performance
    • 8.3.4. Strategic moves and developments
    • 8.3.5. SWOT Analysis
  • 8.4. Tekmira Pharmaceuticals Corp. (Canada)
    • 8.4.1. Company overview
    • 8.4.2. Company snapshots
    • 8.4.3. Business Performance
    • 8.4.4. Strategic moves and developments
      • 8.4.4.1. Principal Strategy
      • 8.4.4.2. Secondary Strategy
    • 8.4.5. SWOT Analysis
  • 8.5. Benitec Biopharma Limited (Australia)
    • 8.5.1. Company overview
    • 8.5.2. Company snapshots
    • 8.5.3. Strategic moves and developments
      • 8.5.3.1. Principal Strategy
      • 8.5.3.2. Secondary Strategy
    • 8.5.4. SWOT Analysis
  • 8.6. Cenix BioScience GmbH (Germany)
    • 8.6.1. Company overview
    • 8.6.2. Company snapshots
    • 8.6.3. Strategic moves and developments
      • 8.6.3.1. Principal Strategy
      • 8.6.3.2. Secondary Strategy
    • 8.6.4. SWOT Analysis
  • 8.7. Genzyme Corporation (USA) (A Sanofi Company)
    • 8.7.1. Company overview
    • 8.7.2. Company snapshots
    • 8.7.3. Business performance
    • 8.7.4. SWOT Analysis
  • 8.8. Silence Therapeutics PLC (UK)
    • 8.8.1. Company overview
    • 8.8.2. Company snapshots
    • 8.8.3. Business performance
    • 8.8.4. Strategic moves and developments
      • 8.8.4.1. Principal Strategy
      • 8.8.4.2. Secondary Strategy
    • 8.8.5. SWOT Analysis
  • 8.9. Sirnaomics, Inc. (USA)
    • 8.9.1. Company overview
    • 8.9.2. Company snapshots
    • 8.9.3. Strategic moves and developments
      • 8.9.3.1. Principal Strategy
      • 8.9.3.2. Secondary Strategy
    • 8.9.4. SWOT Analysis

List of Tables

  • TABLE 1: CONVENTIONAL VS RNA-BASED THERAPEUTICS
  • TABLE 2: TOP INVESTMENT POCKETS OF RNA BASED THERAPEUTICS MARKET (2013)
  • TABLE 3: LIST OF EMA DOCUMENTS AND GUIDELINES
  • TABLE 4: PATENT ANALYSIS BY GEOGRAPHIES(2010-2014)
  • TABLE 5: CLINICAL TRIALS FOR RNA BASED THERAPEUTICS
  • TABLE 6: PIPELINE RNA THERAPEUTICS AND THEIR SPECIFIC TARGET
  • TABLE 7: LIST OF STRATEGIC ALLIANCES FOR THE DEVELOPMENT OF RNA-BASED THERAPEUTICS
  • TABLE 8: LIST OF COMPANIES USING DIFFERENT RNA TECHNOLOGIES
  • TABLE 9: GLOBAL RNA BASED THERAPEUTICS MARKET BY TECHNOLOGIES, 2013 - 2020 ($MILLION)
  • TABLE 10: PRICES OF RNA PURIFICATION KITS
  • TABLE 11: PRICES OF LINEAR AMPLIFICATION KIT
  • TABLE 12: PIPELINE RESEARCH STATUS: RNAI THERAPIES
  • TABLE 13: PRICE CHART FOR SIRNA
  • TABLE 14: COMPANIES AND THEIR MIRNA TECHNOLOGIES
  • TABLE 15: PRICE CHART FOR MIRNA
  • TABLE 16: GLOBAL RNA INTERFERENCE (RNAI) TECHNOLOGY MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 17: GLOBAL RNA ANTISENSE TECHNOLOGY MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 18: GLOBAL RNA BASED THERAPEUTICS MARKET BY APPLICATION, 2013 - 2020 ($MILLION)
  • TABLE 19: GLOBAL RNA BASED THERAPEUTICS CARDIOVASCULAR APPLICATIONS MARKET, BY GEOGRA PHY, 2013 - 2020 ($MILLION)
  • TABLE 20: GLOBAL RNA BASED THERAPEUTICS KIDNEY DISEASES APPLICATIONS MARKET, BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 21: GLOBAL CANCER INCIDENCE, MORTALITY AND PREVALENCE (2012)
  • TABLE 22: GLOBAL RNA BASED THERAPEUTICS ONCOLOGY APPLICATIONS MARKET, BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 23: REGIONAL STATISTICS FOR HIV AND AIDS (2011)
  • TABLE 24: GLOBAL RNA BASED THERAPEUTICS INFECTIOUS DISEASES APPLICATIONS MARKET, BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 25: GLOBAL RNA BASED THERAPEUTICS METABOLIC DISORDERS APPLICATIONS MARKET, BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 26: GLOBAL RNA BASED THERAPEUTICS OTHER APPLICATIONS MARKET, BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 27: GLOBAL RNA BASED THERAPEUTICS MARKET REVENUE, BY END USERS, 2013 - 2020 ($MILLION)
  • TABLE 28: RESEARCH COLLABORATIONS FOR RNA-BASED THERAPEUTICS
  • TABLE 29: REGION/COUNTRIES AND THEIR RESPECTIVE FUNDING AGENCIES
  • TABLE 30: GLOBAL RESEARCH MARKET REVENUE, BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 31: LIST OF RNA BASED THERAPEUTICS : APPROVED AND PHASE IIB & PHASE III CLINICAL TRIALS
  • TABLE 32: GLOBAL THERAPEUTICS MARKET REVENUE, BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 33: RNA DIAGNOSTIC COMPANIES AND THEIR CORE PRODUCTS
  • TABLE 34: GLOBAL DIAGNOSIS MARKET REVENUE, BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 35: GLOBAL RNA BASED THERAPEUTICS MARKET BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 36: NORTH AMERICA RNA BASED THERAPEUTICS MARKET BY APPLICATION, 2013 - 2020 ($MILLION)
  • TABLE 37: UNITED STATES: PIPELINE REVIEW
  • TABLE 38: EUROPE RNA BASED THERAPEUTICS MARKET BY APPLICATION, 2013 - 2020 ($MILLION)
  • TABLE 39: ASIA- PACIFIC RNA BASED THERAPEUTICS MARKET BY APPLICATION, 2013 - 2020 ($MILLION)
  • TABLE 40: LAMEA RNA BASED THERAPEUTICS MARKET BY APPLICATION, 2013 - 2020 ($MILLION)
  • TABLE 41: QUARK PHARMACEUTICALS, INC.
  • TABLE 42: ALNYLAM PHARMACEUTICALS SNAPSHOT
  • TABLE 43: DICERNA PHARMACEUTICALS, INC.SNAP SHOT
  • TABLE 44: TEKMIRA PHARMACEUTICALS CORPORATION SNAP SHOT
  • TABLE 45: BENITEC BIOPHARMA SNAPSHOT
  • TABLE 46: CENIX BIOSCIENCE SNAPSHOT
  • TABLE 47: GENZYME CORPORATION SNAPSHOT
  • TABLE 48: SILENCE THERAPEUTICS PLC SNAPSHOT
  • TABLE 49: SIRNAOMICS, INC SNAPSHOT

List of Figures

  • FIG. 1: TOP FACTORS IMPACTING RNA BASED THERAPEUTICS MARKET (2014-2020)
  • FIG. 2: TOP WINING STRATEGIES FOR RNA BASED THERAPEUTICS MARKET (2011-2013)
  • FIG. 3: TOP WINING STRATEGIES BY SUBTYPE OF DEVELOPMENT
  • FIG. 4: PORTER'S FIVE FORCE ANALYSIS OF RNA BASED THERAPEUTICS MARKET
  • FIG. 5: VALUE CHAIN ANALYSIS OF RNA BASED THERAPEUTICS MARKET
  • FIG. 6: PIPELINE REVIEW OF RNA BASED THERAPEUTICS
  • FIG. 7: PATENT ANALYSIS BY GEOGRAPHIES (2011-2014)
  • FIG. 8: PATENT ANALYSIS BY GEOGRAPHIES BASED ON TECHNOLOGY(2011-2014)
  • FIG. 9: CLINICAL PHASE STATUS: RNAI THERAPIES
  • FIG. 10: CLINICAL PHASE STATUS: ANTISENSE THERAPIES
  • FIG. 11: GLOBAL RENAL DISEASES INCIDENCES: GLOBAL VIEW OF DIALYSIS PATIENTS (2012)
  • FIG. 12: GLOBAL CANCER INCIDENCES BASED ON COMMON CANCER TYPES (2012)
  • FIG. 13: NUMBER OF NEW INFECTIOUS DISEASE CASES IN UNITED STATES (2011)
  • FIG. 14: WHO ESTIMATES OF TUBERCULOSIS INCIDENCE BY WHO REGION (THOUSANDS) (2012)
  • FIG. 15: PREVALENCE OF OBESITY (2013); AGE 20 YEARS AND OLDER (%)
  • FIG. 16: TOP TEN COUNTRIES FOR NUMBER OF PEOPLE WITH DIABETES AGED BETWEEN 20-79 YEARS (2013, MILLION)
  • FIG. 17: SWOT ANALYSIS OF QUARK PHARMACEUTICALS, INC.
  • FIG. 18: ALNYLAM'S NET REVENUE FROM RESEARCH COLLABORATORS (2012)
  • FIG. 19: SWOT ANALYSIS OF ALNYLAM PHARMACEUTICALS, INC.
  • FIG. 20: OPERATING EXPENSES OF DICERNA PHARMACEUTICALS INC. (2013)
  • FIG. 21: SWOT ANALYSIS OF DICERNA PHARMACEUTICALS, INC.
  • FIG. 22: TEKMIRA'S NET REVENUE FROM COLLABORATIONS AND CONTRACTS (2013)
  • FIG. 23: SWOT ANALYSIS OF TEKMIRA PHARMACEUTICALS CORPORATION
  • FIG. 24: SWOT ANALYSIS OF BENITEC BIOPHARMA LIMITED
  • FIG. 25: SWOT ANALYSIS OF CENIX BIOSCIENCE GMBH
  • FIG. 26: BUSINESS PERFORMANCE SANOFI S.A. BY GEOGRAPHIES (2013)
  • FIG. 27: BUSINESS PERFORMANCE OF SANOFI S.A. BY BUSINESS SEGMENTS (2013)
  • FIG. 28: SWOT ANALYSIS OF SANOFI S.A.
  • FIG. 29: BUSINESS PERFORMANCE SANOFI S.A. BY GEOGRAPHIES (2013)
  • FIG. 30: SWOT ANALYSIS OF SILENCE THERAPEUTICS PLC
  • FIG. 31: SWOT ANALYSIS OF SIRNAOMICS, INC.
Back to Top